ClinicalTrials.gg
CompletedNCT03902002Updated May 30, 2025

A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function

A Phase 1 interventional study of Omaveloxolone 50 mg capsules in Hepatic Impairment, sponsored by Biogen. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-30.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2020, 6 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study will examine the pharmacokinetics (PK) of omaveloxolone following a single oral dose of omaveloxolone in subjects with mild, moderate, or severe hepatic impairment compared to healthy subjects with normal hepatic function.

02

Conditions studied

  • Hepatic Impairment

Keywords

  • RTA 408
  • RTA 408 capsules
  • Omaveloxolone
  • Omaveloxolone capsules
  • Hepatic impairment
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females, of any race, between 18 and 70 years of age, inclusive.
  • between 18.0 and 38.0 kg/m2, inclusive, and body weight ≥ 50 kg.
  • Females will not be pregnant (or planning to get pregnant) or lactating at Screening or Check in (Day 1), and females of and males will agree to use .
  • Male subjects must not donate sperm and female subjects must not donate ova from Check in (Day 1) until 90 days after their dose of study drug.

Subjects with Normal Hepatic Function Only

  • Matched to subjects with mild, moderate, or severe hepatic impairment in sex, age (± 10 years), and BMI (± 20%).
  • In good health, determined by no findings from medical history, physical examination, 12 lead , vital signs measurements, and clinical laboratory evaluations (congenital non hemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) at Screening and Check in as assessed by the investigator (or designee).

Subjects with Hepatic Impairment Only

  • Documented chronic stable liver disease ( Class A [mild], B [moderate], or C [severe] at Screening); diagnosis of cirrhosis due to parenchymal liver disease. This will exclude biliary liver cirrhosis or other causes of hepatic impairment not related to parenchymal disorder:
  • 'Documented' is defined by at least one of the following: medical history, physical examination, hepatic ultrasound, computed axial tomography scan, magnetic resonance imaging, and/or liver .
  • 'Chronic stable' is defined as no clinically significant change in disease status within the last 30 days, as documented by the subject's recent medical history (e.g., no worsening of clinical signs of hepatic impairment, or no worsening of total bilirubin or [PT] by more than 50%).
  • Subjects with mild, moderate, or severe hepatic impairment may have medical findings consistent with their hepatic dysfunction, as determined by medical history, physical examination, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations at Screening and Check in (Day 1). Subjects with abnormal findings considered not clinically significant by the investigator will be eligible.

Exclusion criteria

Exclusion Criteria:

  • Significant history or clinical manifestation of any metabolic, allergic, dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
  • History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee).
  • History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (cholecystectomy will not be allowed; uncomplicated appendectomy and hernia repair will be allowed).
  • Presence of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines.
  • Ventricular dysfunction or history of risk factors for Torsade de Pointes (TdP; e.g., unexplained syncope, known long syndrome, heart failure, and cardiomyopathy). Subjects will be excluded if there is a family history of long QT syndrome.
  • Evidence of hepatorenal syndrome and estimated (eGFR) ≤ 60 mL/min/1.73 m2 or abnormal sodium and potassium levels, as determined by the investigator (or designee), calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation at Screening or Check in (Day 1).
  • physical examination abnormality, as determined by the investigator (or designee).
  • Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee).
  • Use of any sensitive substrates for cytochrome P450 (CYP)2C8, moderate or strong inhibitors or inducers of /5, or substrates for p glycoprotein (P gp) within 30 days prior to study drug administration.
  • Consumption of grapefruit, grapefruit products, star fruit, star fruit products, or Seville oranges within 72 hours prior to study drug administration (Day 1) and throughout the study (until after the Follow up Visit).
  • History of alcoholism or drug/chemical abuse within 6 months prior to Check in (Day 1).
  • Alcohol consumption of > 21 units per week for males and > 14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL) wine within the 6 months prior to Check in (Day 1).
  • Positive urine drug screen or positive alcohol breath or urine test result at Screening and Check in (Day 1), that is not otherwise explained by permitted concomitant medications. A positive alcohol test may be repeated once at Screening. A positive alcohol test may not be repeated at Check in (Day 1).
  • Positive test (Appendix 2).
  • Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days or 10 half lives (if known), whichever is longer, prior to dosing.
  • Current enrollment in another clinical study.
  • Receipt of blood products within 2 months prior to Check in.
  • Donation or loss of ≥ 550 mL blood from 3 months prior to Screening, plasma from 2 weeks prior to Screening, or from 6 weeks prior to Screening.

Subjects with Normal Hepatic Function Only

  • Confirmed supine blood pressure > 140 mmHg or \< 90 mmHg and/or supine diastolic blood pressure > 90 mmHg or \< 50 mmHg, or resting (supine) heart rate \< 45 beats per minute (bpm) or > 100 bpm at Screening or Check in (Day 1), with a QT interval corrected for heart rate using Fridericia's method (QTcF) > 450 ms for male subjects and > 470 ms for female subjects.
  • Positive hepatitis panel (Appendix 2).
  • Use of tobacco or nicotine containing products within 6 months prior to Check in (Day 1), or positive cotinine at Screening or Check in (Day 1).
  • Clinically significant abnormal laboratory values (clinical chemistry, hematology, coagulation, and urinalysis), as determined by the investigator (or designee).
  • Significant history or clinical manifestation of hepatic disorder, as determined by the investigator (or designee).
  • History or presence of liver disease or liver injury as indicated by any clinically significant deviations from normal reference ranges in liver function tests, unless approved by the investigator (or designee).
  • History of diabetes mellitus.
  • Use or intend to use any prescription medications/products other than prescribed hormone replacement therapy, implantable, or intrauterine within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee).
  • Use or intend to use slow release medications/products considered to still be active within 30 days prior to Check in (Day 1), unless deemed acceptable by the investigator (or designee).
  • Use or intend to use any non prescription medications/products including vitamins, minerals, and phytotherapeutic , herbal , or plant derived preparations within 7 days prior to Check in (Day 1), unless deemed acceptable by the investigator (or designee).

Subjects with Hepatic Impairment Only

  • Confirmed supine blood pressure > 150 mmHg or \< 90 mmHg and/or supine diastolic blood pressure > 90 mmHg or \< 50 mmHg, or resting (supine) heart rate \< 45 bpm or > 100 bpm at Screening or Check in (Day 1), with a QTcF > 470 ms for both male and female subjects.
  • History of clinically significant left sided heart disease and/or clinically significant cardiac disease.
  • Values outside the normal range for liver function tests that are not consistent with their hepatic condition, as determined by the investigator (or designee).
  • Use of a new medication, or a change in dose, for the treatment of hepatic encephalopathy within 90 days prior to Check in (Day 1).
  • Use of prescription drugs within 30 days prior to Check in (Day 1), with the exception of therapies for hepatic disease and treatment of associated disorders that had been stable for at least 3 months prior to administration of study drug (Day 1) or prescribed hormone replacement therapy, implantable, or intrauterine contraceptives.
  • Recent history of, or the treatment of, esophageal bleeding (within the past 180 days), unless banded.
  • History of unstable diabetes mellitus (as evidenced by [HbA1c] ≥ 9.0% at Screening). Concomitant medications for the treatment of diabetes mellitus must be approved by the investigator (or designee), Sponsor, and Covance Medical Monitor.
  • Presence of a portosystemic shunt.
  • Recent history of paracentesis within 90 days prior to Check in (Day 1).
  • Current functioning organ transplant or awaiting an organ transplant.
  • Evidence of severe ascites.
  • Recent history of hepatic encephalopathy (Grade 2 or above) within 180 days prior to Screening.
  • Smoke more than 10 cigarettes or use the equivalent tobacco or nicotine containing products per day or inability to refrain from tobacco use 2 hours pre dose until 4 hours post dose.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Group 1: matched healthy subjects

    On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.

    Drug: Omaveloxolone 50 mg capsules

  • Experimental
    Group 2: subjects with mild hepatic impairment

    On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.

    Drug: Omaveloxolone 50 mg capsules

  • Experimental
    Group 3: subjects with moderate hepatic impairment

    On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.

    Drug: Omaveloxolone 50 mg capsules

  • Experimental
    Group 4: subjects with severe hepatic impairment

    On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.

    Drug: Omaveloxolone 50 mg capsules

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax) of omaveloxolone in plasma

    Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).

    Time frame: 15 days

  2. Area under the the plasma omaveloxolone concentration-time curve (AUC)

    Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).

    Time frame: 15 days

Secondary outcomes

  1. Count of reported adverse events

    Safety and tolerability will be assessed by counting adverse events, as defined the Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: 15 days

07

Study locations

3 sites
  • Orange County Research Center
    Tustin, California 92780, United States
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Jan 2020, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2019
First posted
Apr 3, 2019
StartActual
Jul 19, 2019
Primary completionActual
Jan 27, 2020
CompletionActual
Jan 27, 2020
Last update
May 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03902002
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Apr 3, 2019
Start date
Jul 19, 2019
Primary completion
Jan 27, 2020
Completion
Jan 27, 2020
Last update
May 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omaveloxolone

Start the discussion